Biomarkers Consortium - Diabetes Drug Development: Identification and Validation of Markers That Predict Long-Term Beta Cell Function and Mass

Predicting beta cell dysfunction in diabetic patients for earlier diagnosis and better treatment

This project completed in December 2018.

The Problem
Some patients with diabetes show dysfunction and diminishment of so-called “beta cells,” which can result in serious health complications. Yet diabetes researchers are unable to identify at-risk patients before they develop these problems.
The Solution
The Beta Cell Project improved methods and tools for assessing diabetes patients’ likelihood of developing beta cell dysfunction/diminishment, ultimately accelerating invention of effective therapies against this complication.

Overview

The Biomarker Consortium’s Diabetes Drug Development: Identification and Validation of Markers That Predict Long-Term Beta Cell Function and Mass (Beta Cell) Project was the first component of a two-stage strategy to characterize beta cell function, with the ultimate aims of using short-term measures to predict long-term beta cell response to interventions and of identifying individuals whose beta cell function may be at risk for rapid deterioration. The Beta Cell Project’s core goal was to evaluate both the Mixed Meal Tolerance Test (MMTT) and Arginine Stimulation Test (AST) against the standard Frequently Sampled Intravenous Glucose Tolerance (FSIGT) Test in a series of clinical studies.

The series of clinical studies proposed in this project provided a foundation for the use of selected methodologies in long-term, multi-center clinical trials in the second stage, a separate project that involved a longitudinal study to qualify short-term markers as predictors of future beta cell function.

Taken together, the work from both stages enabled multiple stakeholders to undertake consistent studies of the pathophysiology and natural history of diabetes, as well as to study therapeutic effects of new interventions more effectively. The Beta Cell Project was a 7-year, $5.1 million project that launched in 2011 and was completed by the end of 2018.

Goals

  • Evaluate MMTT and AST as validated methods in the assessment of beta cell function.
  • Enable development of biomarkers that assess long-term beta cell function, particularly in response to interventions for diabetes.

Partners

Public-Sector Partners

  • National Institute of Diabetes, and Digestive and Kidney Diseases (NIDDK)
  • U.S. Food and Drug Administration (FDA)

Private-Sector Partners:

  • American Diabetes Association*
  • Amylin* / AstraZeneca Pharmeceuticals, LP*
  • Eli Lilly and Company*
  • Janssen
  • Johnson & Johnson*
  • JDRF*
  • Merck*
  • Novartis*
  • NovoNordisk*
  • Pfizer Inc*
  • R-squared Solutions
  • ROI BioPharma
  • Sanofi*
  • Takeda*
  • Wright Biomarker

Academic Partners:

  • Cedars Sinai
  • Joslin Clinic
  • Mayo Clinic
  • University of Padua
  • University of Pennsylvania
  • University of Washington 

*Provided financial or in-kind support for this program.

FNIH Contact

Helen Heymann, MMSC, Scientific Project Manager, Metabolic Disorders; hheymann@fnih.org

Results & Accomplishments

Publications

This project has resulted in several peer-reviewed scientific publications as well as the acceptance of multiple abstracts by the American Diabetes Association and the European Association for the Study of Diabetes meetings.

Clinical Studies

This project has resulted in the completion of four clinical studies.

Novel Methods

This project established a novel decision-making method for use in the design of interventional clinical trials using MMTT and AST with confidence across the glucose tolerance spectrum.

In-House MMT and Arginine Stimulation

This project led to in-house utilization of MMT and Arginine Stimulation at multiple partner companies for drug development decision making, which resulted in significant cost reductions and efficiency gains.

Scientific Publications

Media